Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Diabetic dyslipidaemia
Autore:
Durrington, PN;
Indirizzi:
Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England Univ Manchester Manchester Lancs England M13 9WL M13 9WL, Lancs, England
Titolo Testata:
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
fascicolo: 2, volume: 13, anno: 1999,
pagine: 265 - 278
SICI:
1521-690X(199907)13:2<265:DD>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHOLESTERYL ESTER TRANSFER; LOW-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; VERY-LOW-DENSITY; PLASMA TRIGLYCERIDE; RISK-FACTORS; INSULIN-RESISTANCE; PRIMARY-PREVENTION; APOLIPOPROTEIN-B; TRANSFER PROTEIN;
Keywords:
cholesterol; cholesteryl ester transfer protein; diabetes mellitus; fibrate; high-density lipoprotein; low-density lipoprotein; statin; triglycerides; very-low-density lipoprotein;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
83
Recensione:
Indirizzi per estratti:
Indirizzo: Durrington, PN Univ Manchester, Manchester Royal Infirm, Dept Med, Oxford Rd, Manchester M13 9WL, Lancs, England Univ Manchester Oxford Rd ManchesterLancs England M13 9WL
Citazione:
P.N. Durrington, "Diabetic dyslipidaemia", BEST PRAC R, 13(2), 1999, pp. 265-278

Abstract

The risk of coronary heart disease and atherosclerosis is increased in both Type 2 and Type 1 diabetes mellitus. The dyslipidaemia of Type 2 diabetesconsists of hypertriglyceridaemia and low levels of high-density lipoprotein (HDL) cholesterol. In Type 1 diabetes, hypertriglyceridaemia is also present, but when glycaemic control is good, HDL cholesterol levels may be normal or even increased. In both types of diabetes, nephropathy is associatedwith an exacerbation of hypertriglyceridaemia, a decline in HDL cholesterol level and an increase in serum cholesterol. In the absence of nephropathy, serum cholesterol levels are typically similar to those of the backgroundnon-diabetic population. The risk of coronary heart disease (CHD) associated with serum cholesterol is, however, considerably higher in diabetics than in non-diabetic people, and is much less in diabetic populations living in countries where the average cholesterol level is low, even when hypertension is present. Currently, the strongest evidence that lipid-lowering drug therapy will decrease the risk of CHD, particularly in secondary prevention, comes from trials of statins that lower cholesterol. There is growing experimental and observational evidence that hypertriglyceridaemia. because ofits effects on cholesteryl ester transfer, leading to the formation of a small low-density lipoprotein susceptible to oxidation, compounds the risk of serum cholesterol in diabetes. Both fibrates and statins can decrease this cholesteryl ester transfer. Further studies of fibrates with clinical end-points should clarify their role in the prevention of CHD. In the meantime, statins should be part of routine diabetic clinical practice, fibrates having a more limited role when hypertriglyceridaemia is extreme.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 13:13:50